Drug-coated balloons (DCBs) for femoropopliteal peripheral artery disease (PAD) have been shown to be clinically superior and cost-effective compared to percutaneous transluminal balloon angioplasty (PTA). However, most studies focused on patients without critical limb ischemia (CLI). Our objective was to study the cost-effectiveness of DCB therapy vs. PTA in a CLI patient population in the Dutch healthcare system.
